% | $
Quotes you view appear here for quick access.

Puma Biotechnology, Inc. Message Board

  • doc_3377 doc_3377 Apr 8, 2014 6:33 AM Flag

    Okay. I have a handle on things now.

    It seems like investors were hoping not only for positive data in HER2 + tumors but also HER2 negative rumors. The diarrhea is manageable with high dose Imodium (rate decreased to 5% with this strategy). And even without HER negative rumors neratinib could be a billion dollar drug. It looks better in terms of efficacy than herceptin and that's a $5b drug. Not saying it will displace it but if it gets most of the second and third line then there is still a big enough market to more than justify the current valuation. And if neratinib gets a role in neoadjuvant that it could be a multiple of $1b

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Well, if what your saying it true then those investor are just ignorant of the facts. Neratinib was designed to bind to the kinase domain of the Her2 receptor. If the cancer lacks this receptor, then certainly it will not be effective against such cancers. I would have thought that this would be obvious.

67.05+0.99(+1.50%)Sep 30 4:03 PMEDT